Lord, Abbett & Co
ORKA

Lord, Abbett & Co’s Oruka Therapeutics ORKA Stock Holding History

Lord, Abbett & Co’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.1M Buy
+390,064
New +$26M 0.11% 220

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Lord, Abbett & Co's ORKA Position: Q2 2026 in Review

Lord, Abbett & Co opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 390,064 shares worth $37.1M. The stake represents 0.11% of the portfolio and ranks #220 among its holdings.

255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Lord, Abbett & Co held 390,064 shares of Oruka Therapeutics worth $37.1M as of Q2 2026.
  • Oruka Therapeutics was a new Lord, Abbett & Co position in Q2 2026.
  • Oruka Therapeutics made up 0.11% of Lord, Abbett & Co's portfolio in Q2 2026, its #220 holding.
  • 255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.